{"filing":{"accession_number":"0001493152-26-027641","cik":"0001716166","ticker":"VVOS","company_name":"Vivos Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226027641/form8-k.htm"},"events":[{"id":6294,"run_id":5517,"accession_number":"0001493152-26-027641","anchor_item_number":"2.03","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Vivos Therapeutics received a Nasdaq notice on June 5, 2026, that it failed to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) from April 23 to June 4, 2026. The company has been granted a 180-day compliance period (until December 2, 2026) to regain compliance, with potential for a second 180-day period if certain conditions are met.","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-06-08","submitted_at":null,"items":[{"id":5074,"accession_number":"0001493152-26-027641","item_number":"2.03","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Vivos Therapeutics received a Nasdaq notice on June 5, 2026, that it failed to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) from April 23 to June 4, 2026. The company has been granted a 180-day compliance period (until December 2, 2026) to regain compliance, with potential for a second 180-day period if certain conditions are met. The filing explicitly states that failure to regain compliance within the allotted periods will result in delisting notice and potential removal from listing. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T12:31:08.173880+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":6295,"run_id":5517,"accession_number":"0001493152-26-027641","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Vivos Therapeutics completed an unregistered private placement of a convertible promissory note (the \"V-Co 4 Note\"), exempt from registration under Section 4(a)(2) of the Securities Act, which is convertible into common stock and creates dilution to existing shareholders.","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-06-08","submitted_at":null,"items":[{"id":5075,"accession_number":"0001493152-26-027641","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered private placement of a convertible promissory note (the \"V-Co 4 Note\") by Vivos Therapeutics, exempt from registration under Section 4(a)(2) of the Securities Act. The note is convertible into common stock of the Company, creating dilution to existing shareholders. This is a classic dilutive issuance transaction typical of small-cap biotech companies raising capital through convertible debt.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T12:31:08.173880+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5074,"accession_number":"0001493152-26-027641","item_number":"2.03","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Vivos Therapeutics received a Nasdaq notice on June 5, 2026, that it failed to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) from April 23 to June 4, 2026. The company has been granted a 180-day compliance period (until December 2, 2026) to regain compliance, with potential for a second 180-day period if certain conditions are met. The filing explicitly states that failure to regain compliance within the allotted periods will result in delisting notice and potential removal from listing. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T12:31:08.173880+00:00","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-06-08"},{"id":5075,"accession_number":"0001493152-26-027641","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered private placement of a convertible promissory note (the \"V-Co 4 Note\") by Vivos Therapeutics, exempt from registration under Section 4(a)(2) of the Securities Act. The note is convertible into common stock of the Company, creating dilution to existing shareholders. This is a classic dilutive issuance transaction typical of small-cap biotech companies raising capital through convertible debt.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T12:31:08.173880+00:00","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-06-08"}]}